TY  - JOUR
AU  - Rösener, Nadine
AU  - Gremer, Lothar
AU  - Reinartz, Elke
AU  - König, Anna
AU  - Brener, Oleksandr
AU  - Heise, Henrike
AU  - Hoyer, Wolfgang
AU  - Neudecker, Philipp
AU  - Willbold, Dieter
TI  - A D-enantiomeric peptide interferes with hetero-association of amyloid-β oligomers and prion protein
JO  - The journal of biological chemistry
VL  - 293
SN  - 1083-351X
CY  - Bethesda, Md.
PB  - Soc.
M1  - FZJ-2018-05289
SP  - jbc.RA118.003116 -
PY  - 2018
AB  - Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that affects millions of people worldwide. One AD hallmark is the aggregation of amyloid-β (Aβ) into soluble oligomers and insoluble fibrils. Several studies have reported that oligomers rather than fibrils are the most toxic species in AD progression. Aβ oligomers bind with high affinity to membrane-associated prion protein (PrP), leading to toxic signaling across the cell membrane, which makes the Aβ–PrP interaction an attractive therapeutic target. Here, probing this interaction in more detail, we found that both full-length, soluble human (hu) PrP(23–230) and huPrP(23–144), lacking the globular C-terminal domain, bind to Aβ oligomers to form large complexes above the megadalton size range. Following purification by sucrose density–gradient ultracentrifugation, the Aβ and huPrP contents in these hetero-assemblies were quantified by reversed-phase HPLC. The Aβ:PrP molar ratio in these assemblies exhibited some limited variation depending on the molar ratio of the initial mixture. Specifically, a molar ratio of about four Aβ to one huPrP in the presence of an excess of huPrP(23–230) or huPrP(23–144) suggested that four Aβ units are required to form one huPrP-binding site. Of note, an Aβ-binding all-D-enantiomeric peptide, RD2D3, competed with huPrP for Aβ oligomers and interfered with Aβ–PrP hetero-assembly in a concentration-dependent manner. Our results highlight the importance of multivalent epitopes on Aβ oligomers for Aβ–PrP interactions and have yielded an all-D-peptide-based, therapeutically promising agent that competes with PrP for these interactions.
LB  - PUB:(DE-HGF)16
C6  - pmid:30131337
UR  - <Go to ISI:>//WOS:000447256000001
DO  - DOI:10.1074/jbc.RA118.003116
UR  - https://juser.fz-juelich.de/record/851774
ER  -